Key result
Active CIED-D during LVAD support linked to ~36% lower all-cause mortality.
Why the study?
The impact of carrying a cardiac implantable electronic device with a defibrillator component on outcomes in left ventricular assist device recipients was unclear.
Does an active cardiac implantable electronic device with a defibrillator component reduce all-cause mortality in left ventricular assist device recipients?
Cohort (n=448)
Yes
Does an active cardiac implantable electronic device with a defibrillator component reduce all-cause mortality in left ventricular assist device recipients?
In LVAD recipients, having an active cardiac implantable electronic device with a defibrillator component is associated with significantly better survival.
Answers are grounded in this paper and cite their sources.
Active CIED-D was associated with lower mortality on LVAD support; leaves open whether defibrillator therapy improves outcomes in randomized trials.
AIMS: To compare characteristics of left ventricular assist device (LVAD) recipients receiving a cardiac implantable electronic device (CIED) with a defibrillator component (implantable cardioverter-defibrillator and cardiac resynchronization therapy with defibrillation, CIED-D) vs. those without one, and to assess whether carrying such a device contiguously with an LVAD is associated with outcomes. METHODS AND RESULTS: Overall, 448 patients were analysed (mean age 52 ± 13 years, 82% male) in the multicentre European PCHF-VAD registry. To account for all active CIED-Ds during ongoing LVAD treatment, outcome analyses were performed by a time-varying analysis with active CIED-D status post-LVAD as the time-varying covariate. At the time of LVAD implantation, 235 patients (52%) had an active CIED-D. Median time on LVAD support was 1.1 years (interquartile range 0.5-2.0 years). A reduction of 36% in the risk of all-cause mortality was observed in patients with an active CIED-D [hazard ratio (HR) 0.64, 95% confidence interval (CI) 0.46-0.91; P = 0.012), increasing to 41% after adjustment for baseline covariates (HR 0.59, 95% CI 0.40-0.87; P = 0.008) and 39% after propensity score adjustment (HR 0.61, 95% CI 0.39-0.94; P = 0.027). Other than CIED-D, age, LVAD implant as redo surgery, number of ventricular arrhythmia episodes and use of vasopressors pre-LVAD were remaining significant risk factors of all-cause mortality. Incident ventricular arrhythmias post-LVAD portended a 2.4-fold and 2.6-fold increased risk of all-cause and cardiovascular death, respectively; carrying an active CIED-D remained associated with a 47% and 43% reduction in these events, respectively. CONCLUSIONS: In an analysis accounting for all active CIED-Ds, including those implanted during LVAD support, carrying such a device was associated with significantly better survival during LVAD support.
No takes yet. Share an insight, caveat, or question.
Čikeš et al. (2019) conducted a cohort in Left ventricular assist device (LVAD) recipients (n=448). Cardiac implantable electronic device with a defibrillator component (CIED-D) vs. No active CIED-D was evaluated on All-cause mortality (HR 0.64, 95% CI 0.46-0.91, p=0.012). An active cardiac implantable electronic device with a defibrillator during LVAD support was associated with reduced all-cause mortality.
Synapse has enriched 10 related papers. Consider them for comparative context: